Literature DB >> 25339008

Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.

Irem Saricanbaz1, Eray Karahacioglu, Ozgur Ekinci, Huseyin Bora, Diclehan Kilic, Muge Akmansu.   

Abstract

CD133 is one of the most important stem cell markers in solid cancers and Ki-67 is a marker that reflects cell proliferation. The relationships between the expression of CD133 and Ki-67 and prognosis in gastric carcinoma are unknown and need exploring. We examined 50 gastric cancer patients retrospectively in the Radiation Oncology Department of the Faculty of Medicine, Gazi University. CD133 and Ki-67 expression was examined using immunohistochemical staining. The survival rate in patients with CD133 positive expression was significantly worse than that in the patients with negative expression (p=0.04). Expression of CD133 had a positive correlation with that of Ki-67 (r=0.350; p=0.014). Multivariate analysis revealed that the expression of CD133 was an independent prognostic factor in gastric cancer (p=0.02). Conclusion, expression of CD133 may be a useful prognostic marker in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339008     DOI: 10.7314/apjcp.2014.15.19.8215

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  14 in total

1.  CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression.

Authors:  Rachel Howard; Sameer Al Diffalha; Jose Pimiento; Jaime Mejia; Heiko Enderling; Anna Giuliano; Domenico Coppola
Journal:  Anticancer Res       Date:  2018-08       Impact factor: 2.480

2.  Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma.

Authors:  S Attia; N Atwan; M Arafa; R A Shahin
Journal:  Pathologica       Date:  2019-03

3.  CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer.

Authors:  Alice Nomura; Sulagna Banerjee; Rohit Chugh; Vikas Dudeja; Masato Yamamoto; Selwyn M Vickers; Ashok K Saluja
Journal:  Oncotarget       Date:  2015-04-10

4.  Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.

Authors:  Gyung Hyuck Ko; Se-Il Go; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Dual Energy Spectral CT Imaging in the assessment of Gastric Cancer and cell proliferation: A Preliminary Study.

Authors:  Sai-Ming Cheng; Wei Ling; Jiong Zhu; Jian-Rong Xu; Lian-Ming Wu; Hong-Xia Gong
Journal:  Sci Rep       Date:  2018-12-04       Impact factor: 4.379

6.  Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients.

Authors:  Dan-Dan Xiong; Chu-Mei Zeng; Ling Jiang; Dian-Zhong Luo; Gang Chen
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

7.  Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.

Authors:  Christine Böger; Hans-Michael Behrens; Christoph Röcken
Journal:  J Surg Oncol       Date:  2015-12-28       Impact factor: 3.454

Review 8.  Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.

Authors:  Li Lu; Menglin Wu; Longhao Sun; Weidong Li; Weihua Fu; Xuening Zhang; Tong Liu
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

9.  DIFFERENT CONCENTRATIONS OF SIJUNZI DECOCTION INHIBIT PROLIFERATION AND INDUCE APOPTOSIS OF HUMAN GASTRIC CANCER SGC-7901 SIDE POPULATION.

Authors:  Jun Qian; Jing Li; Jianguang Jia; Xin Jin; Dajun Yu; Chenxu Guo; Bo Xie; Liyu Qian
Journal:  Afr J Tradit Complement Altern Med       Date:  2016-07-03

10.  Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma.

Authors:  Ayesha Ahmed; Dalal M Al-Tamimi
Journal:  Libyan J Med       Date:  2018-12       Impact factor: 1.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.